SCHEMBL7969500

SCHEMBL7969500

Cc1cc(Br)cc(C)c1CO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
ALDH1A1 P00352 7/20 0.34
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
DRD4 P21917 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
NQO2 P16083 1/20 0.32
PGK1 P00558 1/20 0.32
PGK2 P07205 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HPGD P15428 3/20 0.32
SHBG P04278 1/20 0.31
GABRA1 P14867 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31394221 0.86 HTR1D (0.36) HTR1DHTR1BALDH1A1KDM4EHPGD
SCHEMBL29546230 0.84 HTR1D (0.35) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL30937162 0.84 HTR1D (0.35) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL17419026 0.84 HTR1D (0.35) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL20561941 0.84 HTR1D (0.35) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL20562290 0.83 ALDH1A1 (0.36) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL3859523 0.80 HTR1D (0.38) HTR1DHTR1BALDH1A1MEN1KMT2A
SCHEMBL26019034 0.80 NOTUM (0.33) HTR1DHTR1B
SCHEMBL95192 0.78 HRH3 (0.40) HTR1DHTR1BALDH1A1CA2KDM4E
SCHEMBL892872 0.78 CA1 (0.48) HTR1DHTR1BALDH1A1CA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192635-A Mechanically interlocked epoxy resin polymer and preparation method and application thereof 杭州之江有机硅化工有限公司 2025-06-24 CN claimed
CN-102643213-B Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD 2014-04-09 CN claimed
CN-102643213-A Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD 2012-08-22 CN claimed
CN-122094935-A Amide prodrugs and uses thereof 2026-05-26 CN disclosed
CN-112805005-B Thyroxine receptor beta agonist compounds 拓臻股份有限公司 2026-05-12 CN disclosed
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-28 US disclosed
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-07 US disclosed
EP-3840755-B1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS INC (US) 2026-02-18 EP disclosed
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
EP-3080103-B1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN MA INC (US) 2018-04-18 EP disclosed
CN-102643213-B Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD 2014-04-09 CN disclosed
CN-102643213-A Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD 2012-08-22 CN disclosed
CN-101580518-B Process for preparing diphosphine compounds and intermediates useful in the process TAKEDA CHEMICAL INDUSTRIES LTD 2012-05-23 CN disclosed
US-6288101-B1 ADMINISTERING COMPOUNDS SUCH AS 2,6-DIMETHYL-4-ISOPROPYLBENZALDEHYDE TO TREAT INDICATIONS WHERE STIMULATION OF SUBTYPES OF THE SEROTONIN RECEPTOR IS IMPLICATED, SUCH AS MIGRAINES VIRGINIA COMMONWEALTH UNIVERSITY 2001-09-11 US disclosed
US-6124338-A TREATING MIGRAINE HEADACHE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-09-26 US disclosed
US-6048862-A Benzylamidine derivatives with serotonin receptor binding activity VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-04-11 US disclosed
US-5969137-A TREATMENT OF NERVOUS SYSTEM DISORDERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 1999-10-19 US disclosed
WO-1998012183-A1 IMIDAZOLES WITH SEROTONIN RECEPTOR BINDING ACTIVITY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1998-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof ESRRA, FSHR, GPER1 HTR1D 749/4885HTR1B 627/4885ALDH1A1 1356/4885
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof FSHR, CYP19A1, GPER1 HTR1D 500/4885HTR1B 439/4885ALDH1A1 936/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 HTR1D 4379/4885HTR1B 4048/4885ALDH1A1 3818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.